Welcome to the e-CCO Library!

P328: Ustekinumab is an effective and safe therapy in anti-TNF refractory Crohn’s Disease: a two year real-life observational study from Spain
Year: 2021
Source: ECCO'21 Virtual
Authors: Rueda Sanchez, J.(1);Cabello Ramirez, M.(1);Camara Baena, S.(1);Keco Huerga, A.(1);Garcia de la Borbolla Serres, J.(1);Castro Fernandez, M.(1);Grande Santamaria, L.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P329 ECCO grant recipient: preliminary results of the HOT-TOPIC trial (Hyperbaric Oxygen Therapy for the Treatment Of Perianal fistulas In Crohn’s disease)
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Lansdorp1, K. Gecse2, C. Buskens3, M. Löwenberg2, J. Stoker4, W. Bemelman3, G. D’Haens2, R. van Hulst1

Created: Thursday, 30 January 2020, 10:12 AM
P329: Adalimumab therapeutic drug monitoring test validated for measuring ABP 501 biosimilar
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. B. Ruiz-Argüello1, A. Maguregui1, A. Martínez1, D. Nagore1

Created: Friday, 22 February 2019, 9:41 AM
P329: Comparative Assessment of Adalimumab Trough Levels between Point-of-Care Testing and current Standard of Care (enzyme linked immunosorbent assay) in patients with Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Marsilio, I.(1);MANIERO, D.(1);Lorenzon, G.(1);Rigo, A.(1);Cardin, R.(1);Facchin, S.(1);Barberio, B.(1);D'Incà, R.(1);Zingone, F.(1);Bahur, B.(2);Bray, K.B.(3);Savarino, E.V.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P329: Effect of adalimumab dose escalation on clinical, health-related quality of life, treatment satisfaction and work productivity outcomes among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Travis S.*1, Feagan B.2, Peyrin-Biroulet L.3, Panaccione R.4, Danese S.5, Lazar A.6, Robinson A.7, Thakkar R.7, Pappalardo B.7, Petersson J.7, Bereswill M.6, Chen N.7, Skup M.7

Created: Wednesday, 20 February 2019, 10:36 AM
P329: Infliximab biosimilar in the treatment of inflammatory bowel disease: a Japanese single-cohort observational study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Hamanaka*, T. Nakagawa, H. Koseki, T. Sakurai, T. Taida, K. Okimoto, K. Saito, D. Maruoka, T. Matsumura, T. Katsuno, M. Arai, O. Yokosuka

Created: Friday, 22 February 2019, 9:49 AM
P329: Stool multiplex molecular PCR assay in comparison to conventional stool tests for detecting gastrointestinal infections as cause of flares in Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kutar, M.(1)*;Desai, D.(2);Abraham, P.(2);Gupta, T.(2);
Created: Friday, 14 July 2023, 11:05 AM
P329: Utility of faecal calprotectin to assess Crohn’s disease activity in patients with an ileostomy
Year: 2018
Source: ECCO '18 Vienna
Authors:

C.R. Rowan1*, S. Alzubi2, M. Healy3, G. Cullen4, H. Mulcahy4, J. Sheridan3,4, G.A. Doherty4

Created: Thursday, 21 February 2019, 9:14 AM
P329: Which should come first? Surgery or biologic therapy for ileocaecal Crohn’s disease in biologic naïve patients
Year: 2022
Source: ECCO'22
Authors: Witjes, C.(1,2);Patel, A.(1,3);Zocche, D.(1);van 't Hullenaar- , C.(1);Cripps, S.(4);Travis, S.(5);George, B.(1);
Created: Friday, 11 February 2022, 3:52 PM
P330 Inflammatory Bowel Disease (IBD) patients frequently report adverse drug reactions during biologic therapy: A multicentre, prospective, patient-reported pharmacovigilance monitoring system
Year: 2020
Source:

ECCO'20 Vienna

Authors:

P. THOMAS1, R. West2, M. Russel3, J. Jansen4, J. van Lint5, N. Jessurun5, T. Römkens6, F. Hoentjen1

Created: Thursday, 30 January 2020, 10:12 AM
P330: A national survey on therapeutic education in inflammatory bowel disease by an association of caregivers and expert patients: French Association for Therapeutic Education in inflammatory bowel disease (AFEMI)
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Moreau1, E. Balez2, C. Devos3, X. Hébuterne4, M. Veltin5, M. Allez*6

Created: Friday, 22 February 2019, 9:41 AM
P330: A prospective trial to evaluate the feasibility of a mobile app in patients with inflammatory bowel disease under maintenance therapy
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Coenen1*, E. Weyts1, P. Geens1, E. Nijns2, R. Van Durm2, M. Ferrante1, S. Vermeire1, B. Van den Bosch2, G. Van Assche1

Created: Thursday, 21 February 2019, 9:14 AM
P330: Discontinuation of corticosteroids among ulcerative colitis patients treated with vedolizumab in the United States
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Patel H.*1, Chastek B.2, Null K.D.3, Demuth D.4

Created: Wednesday, 20 February 2019, 10:36 AM
P330: Immunity in patients with inflammatory bowel disease on biologic therapy after COVID 19 vaccination
Year: 2022
Source: ECCO'22
Authors: Knezevic, T.(1);Cujic, D.(2);Odanovic, O.(1);Kralj, D.(1);Gnjatovic, M.(2);Kalaba, A.(1);Vrinic Kalem, D.(1);Svorcan, P.(1,3);Markovic, S.(1,3);
Created: Friday, 11 February 2022, 3:52 PM
P330: Long-term outcomes following a switch from originator adalimumab to the biosimilar SB5 (Imraldi) in IBD
Year: 2021
Source: ECCO'21 Virtual
Authors: Derikx, L.(1,2);Dolby, H.(2);Plevris, N.(2);Lucaciu , L.(2);Rees, C.(2);Lyons, M.(2);Siakavellas, S.(2);Constantine-Cooke, N.(3);Noble, C.(2);O’Hare, C.(2);Merchant, L.(2);Arnott, I.(2);Jones, G.R.(2,4);Lees, C.(2,5);
Created: Wednesday, 2 June 2021, 4:12 PM
P330: Ultrasound remission after biologic induction predicts long-term endoscopic remission in Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Allocca, M.(1)*;Dell'Avalle , C.(2);Furfaro, F.(3);Zilli, A.(3);Radice, S.(3);D'Amico, F.(3);Peyrin-Biroulet, L.(4);Fiorino, G.(3);Danese, S.(3);
Created: Friday, 14 July 2023, 11:05 AM
P330: Vitamin D insufficiency in patients with inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. d. C. Martos Plasencia*, C. Verdejo Gil, R. H. Lorente Poyatos, E. De la Santa Belda, M. Peña Gómez, R. Salmoral Luque, B. López Viedma, J. Olmedo Camacho

Created: Friday, 22 February 2019, 9:49 AM
P331 Productivity loss in patients with inflammatory bowel disease receiving treatment for iron deficiency anaemia: A comparison of ferric maltol and IV iron
Year: 2020
Source: ECCO'20 Vienna
Authors: S. Howaldt1, I. Jacob2, M. Sampson3, F. Akriche4
Created: Thursday, 30 January 2020, 10:12 AM
Last Modified: Wednesday, 3 March 2021, 4:12 PM by Dauren Ramankulov

Corrigendum:

In the originally published version of this poster presentation, the below corrections have been made.

Upon the original publication, the Results section indicated that the primary non-inferiority endpoint was met. This should have read: “The primary non-inferiority endpoint was not met."

P331: Allopurinol and azathioprine co-therapy or thioguanine dose splitting: shifting the shunters in the mercaptopurine pathway in a paediatric inflammatory bowel disease population—a single-centre experience
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Chadokufa*1, A. Lozinsky Rolnik2, S. Sider1, N. Acton3, B. Huggett3, N. Shah4, F. Kiparissi1

Created: Friday, 22 February 2019, 9:49 AM
P331: Composite outcomes in Crohn’s disease: a systematic review and meta-analysis of observational studies
Year: 2022
Source: ECCO'22
Authors: Estevinho, M.M.(1);Sottomayor, C.(2);Alves, C.(3);Santago, M.(4);Ministro, P.(5);Lago, P.(6);Correia, L.(7);Gonçalves, R.(8);Carvalho, D.(9);Portela, F.(10);Dias, C.C.(11);Dignass, A.(12);Danese, S.(13);Peyrin-Biroulet, L.(14);Magro, F.(15);
Created: Friday, 11 February 2022, 3:52 PM